We have established an anti-CD14 mAb named 4C1 against murine macrophages. 4C1 can bind to thioglycolate-elicited peritoneal macrophages, bone marrow-derived macrophages and casein-induced peritoneal neutrophils. Immunostaining with 4C1 was inhibited by treatment of the cells with phosphatidylinositol specific phospholipase C, suggesting that the antigen is GPI-anchored. Immunoprecipitates from biotin-labeled RAW264.7 cell lysate with 4C1 were around 55 kDa and were visualized with rmC5-3, the only commercially available anti-murine CD14 mAb. 4C1 positively stained COS7 cells transfected with an expression vector containing cDNA of murine CD14. Pretreatment of macrophages with 4C1 reduced LPS-mediated production of TNFα, IL-6, and nitrite. The binding of FITC-LPS to RAW264.7 cells was blocked by pretreatment with 4C1 but not with rmC5. Pretreatment of cells with unlabeled 4C1 mAb but not unlabeled rmC5-3 reduced binding of FITC-4C1. These results suggest that the 4C1 epitope on murine CD14 plays an important role in LPS binding and is distinct from the rmC5-3 epitope.
References
1.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JCCD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science1990; 249: 1431—1433.
2.
Ulevitch RJ, Mathison JC, Schumann RR, Tobias PSA new model of macrophage stimulation by bacterial lipopolysaccharide. J Trauma1990; 30: S189—S192.
3.
Wright SD, Ramos RA, Hermanowski-Vosatka A., Rockwell P., Detmers PAActivation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14. J Exp Med1991; 173: 1281—1286.
4.
Yu B., Wright SDCatalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem1996; 271: 4100—4105.
5.
Heumann D., Gallay P., Barras C. et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol1992; 148: 3505—3512.
6.
Cleveland MG , Gorham JD, Murphy TL, Tuomanen E., Murphy KMLipoteichoic acid preparations of Gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun1996; 64: 1906—1912.
7.
Savedra Jr R. , Delude RL, Ingalls RR, Fenton MJ, Golenbock DTMycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system . J Immunol1996; 157: 2549—2554.
8.
Kusunoki T., Wright SDChemical characteristics of Staphylococcus aureus molecules that have CD14-dependent cell-stimulating activity. J Immunol1996; 157: 5112—5117.
9.
Weidemann B. , Schletter J., Dziarski R. et al. Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Infect Immun1997; 65: 858—864.
10.
Bosco MC, Espinoza-Delgado I., Rowe TK, Malabarba MG, Longo DL, Varesio L.Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. J Immunol1997 ; 159: 2922—2931.
11.
Wang PY, Kitchens RL, Munford RSPhosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J Biol Chem1998; 273: 24309—24313.
12.
Schimke J., Mathison J., Morgiewicz J., Ulevitch RJAnti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA1998; 95: 13875—13880.
13.
Adachi Y., Suzuki Y., Ohno N., Yadomae T.Adjuvant effect of grifolan on antibody production in mice. Biol Pharm Bull1998; 21: 974—977.
14.
Matsuura K. , Ishida T., Setoguchi M., Higuchi Y., Akizuki S., Yamamoto S.Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med1994 ; 179: 1671—1676.
15.
Yang RB, Mark MR, Gray A. et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature1998; 395: 284—288.
Schumann RRFunction of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review . Res Immunol1992; 143: 11—15.
18.
Goyert SM, Hazio A., Jiao D. et al. CD14 cluster workshop report. Leukocyte Typing V1995; 778—782.
19.
Yamamoto S. , Matsuura K., Ishida T. et al. Characterization and use of mAb against mouse CD14. Leukocyte Typing V1995; 788—790.
20.
Perera PY, Vogel SN, Detore GR, Haziot A., Goyert SMCD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol . J Immunol1997; 158: 4422—4429.
21.
Vogel SN, Perera PY, Detore GR et al. CD14 dependent and independent signaling pathways in murine macrophages from normal and CD14 `knockout' (CD14KO) mice stimulated with LPS or taxol. Prog Clin Biol Res1998; 397: 137—146.
22.
Yamamoto S. , Tamura Y., Higuchi Y. et al. Roles of CD14 in LPS signaling and scavenging: analysis of CD14- transgenic and non-transgenic mice and rats in response to LPS. Prog Clin Biol Res1998 ; 397: 89—96.
23.
Hetherington CJ, Kingsley PD, Crocicchio F. et al. . Characterization of human endotoxin lipopolysaccharide receptor CD14 expression in transgenic mice. J Immunol1999; 162: 503—509.
24.
Pedron T., Girard R., Chaby R.Variation of LPS-binding capacity, epitope expression, and shedding of membrane-bound CD14 during differentiation of human monocytes. J Immunol1995; 155: 1460—1471.
25.
Stelter F., Bernheiden M., Menzel R. et al. Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Eur J Biochem1997; 243: 100—109.
26.
Juan TS, Hailman E., Kelley MJ et al. Identification of a lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J Biol Chem1995; 270: 5219—5224.
27.
Kirikae F., Kirikae T., Qureshi N., Takayama K., Morrison DC, Nakano M.CD14 is not involved in Rhodobacter sphaeroides diphosphoryl lipid A inhibition of tumor necrosis factor alpha and nitric oxide induction by taxol in murine macrophages. Infect Immun1995; 63: 486—497.
